American Medical Writers Association (AMWA), Rockville, MD, USA; International Society for Medical Publication Professionals (ISMPP), Fort Lauderdale, FL, USA.
Consultant Medical Affairs, Bayer AG, Hamburg, Germany.
Curr Opin Pharmacol. 2021 Jun;58:83-89. doi: 10.1016/j.coph.2021.04.002. Epub 2021 May 13.
Men with obesity and/or type 2 diabetes (T2D) have a high prevalence of testosterone deficiency (TD). Similarly, men with TD have an increased risk of developing obesity and/or T2D, and further body fat accumulation and deterioration of glycemic control create a vicious cycle. The landmark testosterone for diabetes mellitus trial, the largest randomized controlled trial of testosterone therapy (TTh) to date, confirms the beneficial effects of TTh on fat loss and gain in muscle mass, and that TTh for 2 years significantly reduces the risk of incident T2D, and may also reverse T2D. The testosterone for diabetes mellitus trial suggests that TTh reduces the risk of T2D and results in greater improvement in sexual function and wellbeing, beyond lifestyle intervention alone.
患有肥胖症和/或 2 型糖尿病（T2D）的男性，其睾酮缺乏症（TD）的发病率较高。同样，患有 TD 的男性患肥胖症和/或 T2D 的风险增加，并且进一步的体脂积累和血糖控制恶化会形成恶性循环。具有里程碑意义的糖尿病睾酮试验是迄今为止最大的睾酮治疗（TTh）随机对照试验，证实了 TTh 对脂肪减少和肌肉质量增加的有益作用，并且 TTh 治疗 2 年可显著降低 T2D 的发病风险，并且还可能逆转 T2D。糖尿病的睾酮试验表明，TTh 可降低 T2D 的风险，并使性功能和幸福感得到更大改善，这超出了单纯的生活方式干预。
